Last reviewed · How we verify
Remifentanil and/or propofol
Remifentanil is a potent, short-acting opioid analgesic used for anesthesia, while propofol is a short-acting sedative-hypnotic agent used for anesthesia induction and maintenance.
Remifentanil is a potent, short-acting opioid analgesic used for anesthesia, while propofol is a short-acting sedative-hypnotic agent used for anesthesia induction and maintenance. Used for General anesthesia, Sedation for mechanical ventilation.
At a glance
| Generic name | Remifentanil and/or propofol |
|---|---|
| Sponsor | Alder Hey Children's NHS Foundation Trust |
| Drug class | Opioid analgesic, Sedative-hypnotic |
| Target | Opioid receptors, GABA_A receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 3 |
Mechanism of action
Remifentanil works by binding to opioid receptors in the brain, spinal cord, and other areas, producing analgesia and sedation. Propofol, on the other hand, acts on the GABA_A receptor, enhancing the inhibitory effects of GABA, leading to sedation and hypnosis.
Approved indications
- General anesthesia
- Sedation for mechanical ventilation
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
Key clinical trials
- The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
- Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surgery. (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- General Anesthesia vs Conscious Sedation for Radial Endobronchial Ultrasound (NA)
- Tubeless Strategy in Lung Transplantation: A Prospective Single-Arm Study (NA)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- Continuous Versus 1-min Oscillometric Arterial BP Monitoring (NA)
- Dexmedetomidine and Myocardial Protection (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil and/or propofol CI brief — competitive landscape report
- Remifentanil and/or propofol updates RSS · CI watch RSS
- Alder Hey Children's NHS Foundation Trust portfolio CI